Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

The U.K.’s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc’s (NASDAQ:AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). • AUTL stock is showing exceptional strength. Get the market research here.Acute lymphoblastic leukemia is a cancer of the blood and bone marrow ...